Privia Health Group (PRVA) Stock Price, News & Analysis

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Privia Health Group in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRVA shares.
View PRVA analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 12-month target prices for Privia Health Group's shares. Their PRVA share price targets range from $21.00 to $40.00. On average, they predict the company's share price to reach $28.18 in the next year. This suggests a possible upside of 56.3% from the stock's current price.
View analysts price targets for PRVA or view top-rated stocks among Wall Street analysts.

Privia Health Group's stock was trading at $23.03 on January 1st, 2024. Since then, PRVA shares have decreased by 21.7% and is now trading at $18.03.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PRVA earnings forecast.

Privia Health Group will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Privia Health Group, Inc. (NASDAQ:PRVA) released its earnings results on Tuesday, February, 27th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.02. The business had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. Privia Health Group had a net margin of 1.39% and a trailing twelve-month return on equity of 3.97%. The business's quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 earnings per share.

ETFs with the largest weight of Privia Health Group (NASDAQ:PRVA) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), BNY Mellon Innovators ETF (BKIV), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Fidelity Disruptive Medicine ETF (FMED) and Franklin Genomic Advancements ETF (HELX).

Privia Health Group issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.9 billion.

Privia Health Group (PRVA) raised $351 million in an initial public offering on Thursday, April 29th 2021. The company issued 19,500,000 shares at $17.00-$19.00 per share. Goldman Sachs, J.P. Morgan, Credit Suisse, Piper Sandler and William Blair served as the underwriters for the IPO and Canaccord Genuity, Truist Securities, R. Seelaus & Co. and Siebert Williams Shank were co-managers.

Privia Health Group's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.05%), Los Angeles Capital Management LLC (0.03%), Guidance Capital Inc. (0.02%), Allspring Global Investments Holdings LLC (0.01%) and Park Place Capital Corp (0.00%). Insiders that own company stock include Advisors LLC Mbd, David Mountcastle, Jeffrey B Butler, Jeffrey Daniel Bernstein, Matthew Shawn Morris, Pamplona Capital Partners Iii,, Parth Mehrotra, Thomas Bartrum and William M Sullivan.
View institutional ownership trends.

Shares of PRVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.